Latest News and Press Releases

Dublin, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a...

SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...

Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Gene Therapy Market" has been added to ResearchAndMarkets.com's offering. The gene therapy market is forecasted to expand significantly, with a...

HOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells...

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Adeno Associated Virus Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Spine Biologic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Human Raw Materials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Automated and Closed Cell Therapy Processing Systems Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added...

HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based...

FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study